Gsk (GSK) Share-based Compensation (2009 - 2015)
Gsk (GSK) posted quarterly Share-based Compensation of $558.4 million for Q4 2015, up 6.16% year-over-year from $526.0 million in Q4 2014, and up 6.16% quarter-over-quarter from $526.0 million in Q4 2014.
Gsk (GSK) Share-based Compensation (2009 - 2015) Analysis & Trends
Gsk's Share-based Compensation history runs 7 years deep, the most recent figure standing at $558.4 million for Q4 2015.
- In Q4 2015, Share-based Compensation rose 6.16% year-over-year to $558.4 million; the TTM figure through Dec 2015 stood at $2.0 billion (up 14.49% YoY), while the FY2018 annual figure was $480.8 million, up 12.08% from the prior year.
- Share-based Compensation for Q4 2015 stood at $558.4 million, up from $526.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $558.4 million in Q4 2015, with the low at $311.2 million in Q4 2011.
- The 5-year median for Share-based Compensation is $516.5 million (2013), against an average of $453.1 million.
- The sharpest annual moves came in 2013 and 2014: Share-based Compensation jumped 46.19% in 2013, then increased 1.85% in 2014.
- Gsk's Share-based Compensation stood at $311.2 million in 2011, then climbed by 13.54% to $353.3 million in 2012, then soared by 46.19% to $516.5 million in 2013, then climbed by 1.85% to $526.0 million in 2014, then increased by 6.16% to $558.4 million in 2015.
- Business Quant data shows GSK's Share-based Compensation at $558.4 million in Q4 2015, $526.0 million in Q4 2014, and $516.5 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.97 Bn | 635.21 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 470.01 Bn | 463.44 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 380.54 Bn | 373.40 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 302.93 Bn | 295.24 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.10 Bn | 253.20 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.12 Bn | 223.14 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 183.14 Bn | 179.96 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.87 Bn | 101.71 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.06 Bn | 47.68 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 558.44 Mn |
| Dec 31, 2015 | 558.44 Mn |
| Dec 31, 2014 | 526.02 Mn |
| Dec 31, 2014 | 526.02 Mn |
| Dec 31, 2013 | 516.48 Mn |
| Dec 31, 2013 | 516.48 Mn |
| Dec 31, 2012 | 353.29 Mn |
| Dec 31, 2012 | 353.29 Mn |
| Dec 31, 2011 | 311.17 Mn |
| Dec 31, 2011 | 311.17 Mn |
| Dec 31, 2010 | 282.80 Mn |
| Dec 31, 2010 | 282.80 Mn |
| Dec 31, 2009 | 292.39 Mn |
| Dec 31, 2009 | 292.39 Mn |